Researchers
-
Begoña Pina Marín
Ophthalmology
-
Carlos Luis Moser Würth
Ophthalmology
-
Carlos Martínez Belló
Ophthalmology
-
Diana Paola Mora Ramirez
Ophthalmology
-
Joan Josep Escobar Barranco
Ophthalmology
-
Josep Badal Lafulla
Ophthalmology
Phd -
Luis Amselem Gómez
Ophthalmology
-
Magela Garat Chifflet
Ophthalmology
-
Manel Fernández Bonet
Ophthalmology
-
Monica Lecumberri López
Ophthalmology
-
Rafael Alcubierre Bailac
Ophthalmology
-
Sabrina Bojados
Ophthalmology
-
Stephanie Carrillo
Ophthalmology
Contact the group
Form
Projects
-
Ophthalmology
Researcher
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Phase III, multicenter, randomized, double-masked, two-group, 18-month study evaluating the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to central vein occlusion the retina (RAVEN).
-
DISTRICT ATTORNEY:
Novartis Pharmaceutica SA
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Phase IIIb, multicenter, randomized, double-masked, two-group, 64-week study evaluating the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treatment-to-control regimen in patients with associated neovascular macular degeneration at the age (TALON).
-
DISTRICT ATTORNEY:
Novartis
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Phase 2, multicenter, prospective, randomized, double-masked, active comparator-controlled study to investigate the efficacy and safety of repeated intravitreal administration of KSI-301 in subjects with neovascular (wet) age-related macular degeneration.
-
DISTRICT ATTORNEY:
Kodiak Sciences Inc.
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Registry of patients with retinal diseases treated with intravitreal therapies. National multicenter observational postauthorization study.
-
DISTRICT ATTORNEY:
CLINICAL FOUNDATION FOR BIOMEDICAL RESEARCH
-
TYPE E:
EPA-SP
-
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Phase III, multicenter, randomized, double-masked, two-group, 18-month study evaluating the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to central vein occlusion of the retina (RAVEN).
-
DISTRICT ATTORNEY:
Novartis Pharmaceutica SA
-
TYPE E:
RD2015
-
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Phase IIIb, multicenter, randomized, double-masked, two-group, 64-week study evaluating the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treatment-to-control regimen in patients with associated neovascular macular degeneration at the age (TALON).
-
DISTRICT ATTORNEY:
Novartis
-
TYPE E:
RD2015
-
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Phase 2, multicenter, prospective, randomized, double-masked, active comparator-controlled study to investigate the efficacy and safety of repeated intravitreal administration of KSI-301 in subjects with neovascular (wet) age-related macular degeneration.
-
DISTRICT ATTORNEY:
Kodiak Sciences Inc.
-
TYPE E:
RD2015
-
- Year 2019
- Dos de Maig Hospital Integral Care Center
Phase 2, multicenter, prospective, randomized, double-masked, active comparator-controlled study to investigate the efficacy and safety of repeated intravitreal administration of KSI-301 in subjects with neovascular (wet) age-related macular degeneration.
-
DISTRICT ATTORNEY:
Kodiak Sciences Inc.
-
TYPE E:
RD2015
-
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Registry of patients with retinal diseases treated with intravitreal therapies. National multicenter observational postauthorization study.
-
DISTRICT ATTORNEY:
CLINICAL FOUNDATION FOR BIOMEDICAL RESEARCH
-
TYPE E:
EPA-SP
-
Ophthalmology
Researcher
- Year 2018
- Comprehensive Care Center Dos de Maig Hospital
Randomized, double-masked, placebo-controlled and exploratory trial to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1467335 administered orally for 12 weeks with a 12-week follow-up period in patients with non-proliferative diabetic retinopathy without macular edema central predominance diabetic
-
DISTRICT ATTORNEY:
Boehringer Ingelheim España, SA
-
TYPE E:
RD2015
Lines of action
- Treatment of retinal diseases with intravitreal medication
- Anti VEGF in diabetic macular edema
- Anti VEGF in central serous chorioretinopathy
- Treatment of Diabetic Retinopathy
- UTI (Intravitreal Therapy Unit)
- New techniques in cataract surgery
- Surgical alternatives to full thickness corneal transplantation
- Microkeratum assisted keratoplasty Anterior and posterior lamellar techniques
